Burrell Terry-Ann's Form 4 filing
Recursion Pharmaceuticals, Inc. (RXRX) · filed Jul 14, 2023
- Accession no.
- 0001209191-23-042305
- Filed
- Jul 14, 2023
- Trade date
- Jul 12-13, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 5 non-derivative transactions. Open-market sales total $1.41M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Burrell Terry-AnnCIK 0001786484 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 12, 2023 | Class A Common Stock | SSaleDisposed | −24,302 | $11.25F2 | −$273,397.5 | 147,545 | Direct | |
| Jul 12, 2023 | Class A Common Stock | SSaleDisposed | −78,071 | $12.15F3 | −$948,562.65 | 69,474 | Direct | |
| Jul 12, 2023 | Class A Common Stock | SSaleDisposed | −3,195 | $13.18F4 | −$42,110.1 | 66,279 | Direct | |
| Jul 12, 2023 | Class A Common Stock | SSaleDisposed | −3,157 | $14.08F5 | −$44,450.56 | 63,122 | Direct | |
| Jul 13, 2023 | Class A Common Stock | SSaleDisposed | −8,275 | $12.59F6 | −$104,182.25 | 54,847 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $10.60 to $11.59 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.
Referenced by the price of 1 transaction in Table I.
- F3
The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $11.60 to $12.54 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.
Referenced by the price of 1 transaction in Table I.
- F4
The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $12.76 to $13.72 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.
Referenced by the price of 1 transaction in Table I.
- F5
The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $13.81 to $14.56 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.
Referenced by the price of 1 transaction in Table I.
- F6
The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $12.105 to $12.98 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.
Referenced by the price of 1 transaction in Table I.